Sourav Bandyopadhyay, PhD

Associate Professor
+1 415 476-3425
Research Description: 

Our lab focuses on methods to map pathway rewiring in cancer. Our major goal is to understand at the systems level how the biological networks within cancer cells are fundamentally different from that in normal cells. Using our technologies, we intend to develop platforms for the rational application of personalized medicine and design of combination cancer therapies.

Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
Research Summary: 
Computational and experimental approaches to guide the development of new precision medicines for cancer



Targeting the evolution of drug resistance in lung cancer.

Molecular & cellular oncology

Shah KN, Bandyopadhyay S

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

Nature medicine

Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S

P1.13-10 Aurora Kinase A Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer.

Journal of Thoracic Oncology

K. Shah, C. Blakely, T. Bivona, S. Bandyopadhyay

Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.

Nature chemical biology

Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S